CinCor Pharma, Inc. (NASDAQ: CINC)

Engel Law PLLC is investigating whether fair value to CinCor shareholders will result from the proposed sale of CinCor Pharma, Inc. (NASDAQ: CINC) to AstraZeneca for $26.00 per share in cash plus a non-tradable contingent value right of $10.00 per share in cash.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

CinCor Pharma, Inc.

MM slash DD slash YYYY